Lucite tombstone celebrating Series A funding for Trailhead Biosystems. The Cleveland-based biotechnology company is focused on the application of machine-enabled technology.
(21ADH001)acf domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/u393780522/domains/cpresence.com/public_html/wp-includes/functions.php on line 6131Lucite tombstone celebrating Series A funding for Trailhead Biosystems. The Cleveland-based biotechnology company is focused on the application of machine-enabled technology.
(21ADH001)Crystal deal toy commemorating the launch of San Francisco-based GoodFinch Fund III.
(20ALJ462)Custom Lucite tombstone celebrating the close of Navegar II. The fund, raised by Manila-based private equity firm Navegar, will focus on the consumer and business services sectors in the Philippines.
(20ALJ190)Custom crystal from the Bill and Melinda Gates Foundation recognizing the contributions to the Global Vaccine Summit. The 2020 “Gavi” conference, held virtually due to COVID-19, included 42 heads of state and government.
(20LJW152)Crystal financial tombstone commemorating the acquisition of the Falls at Lakewood. The 96-unit apartment complex, located in Lakewood, Colorado, was acquired by Los Angeles-based Clear Capital.
(20ALJ295)Crystal deal toy commemorating the acquisition of Philadelphia-based Spark Therapeutics. The acquiring firm, Swiss pharmaceutical firm Roche, is headquartered in Basel.
(9ALJ621)Billie Jean King Youth Leadership Award presented to Joel Apudo at the 2020 ESPN Espy Awards ceremony. Apudo manages a youth soccer program in the West End neighborhood of Atlanta.
(20AKL184)Custom deal toy commemorating a secured term loan for Saavi Energia, the largest privately held power generator in Mexico.
(20AJH173)Crystal tombstone commemorating an exclusive licensing agreement between Ovid Therapuetics and Angelini Pharma. The agreement centers on the development, manufacturing, and commercialization of a potential treatment for Angelman syndrome.
(20AJH130)